Marinomed reported encouraging Q3/2019 results, with revenues matching those reported in H1/2019, suggesting that the marketed Carragelose products are back on track. This offset the expected increase in operating expenses, leading to a narrower operating loss vs. previous 2019 quarters and Q3/2018. Our revised forecasts assume total 2019E revenues of €5.7m (+6% YoY) and operating loss of €6.7m (vs. €5.1m in 2018), and we continue to anticipate sustained profitability from 2022
06 Dec 2019
Budesolv partnership the next key event
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Budesolv partnership the next key event
- Published:
06 Dec 2019 -
Author:
Brigitte de Lima, PHD CFA -
Pages:
12
Marinomed reported encouraging Q3/2019 results, with revenues matching those reported in H1/2019, suggesting that the marketed Carragelose products are back on track. This offset the expected increase in operating expenses, leading to a narrower operating loss vs. previous 2019 quarters and Q3/2018. Our revised forecasts assume total 2019E revenues of €5.7m (+6% YoY) and operating loss of €6.7m (vs. €5.1m in 2018), and we continue to anticipate sustained profitability from 2022